At the Lung Cancer Translational and Integrative Pathology Lab, we bridge clinical gaps through a multi-modal research strategy focused on real-world impact. Our work spans three core axes: enhancing lung cancer detection through biomarker-driven screening and classification; improving early-stage management by identifying predictors of relapse; and advancing treatment of late-stage disease by uncovering biomarkers of immunotherapy response. By integrating pathology, genomics, and spatial technologies, we aim to transform lung cancer care from diagnosis to therapy.